In the case of continuous dependence on oncogenes, the concept of differential resistance is of great significance for cancer treatment and contributes to the clinical progress of a new generation of FGFR4 inhibitors, which considers resistance mechanisms while maintaining selectivity for FGFR4. This evidence concerns the gene FGFR4 and cancer.